IFRX - InflaRx N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.3200
+0.1700 (+5.40%)
At close: 4:00PM EDT

3.3200 0.00 (0.00%)
After hours: 7:05PM EDT

Stock chart is not supported by your current browser
Previous Close3.1500
Open3.1600
Bid3.2900 x 3000
Ask3.3300 x 1400
Day's Range3.1500 - 3.3400
52 Week Range2.9100 - 53.1000
Volume1,189,744
Avg. Volume1,303,576
Market Cap86.202M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire4 days ago

    InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum

    InflaRx N.V. (IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the treatment of the first patient in a phase IIa clinical trial evaluating the Company’s lead product candidate, IFX-1, in Pyoderma Gangraenosum. Pyoderma Gangraenosum (PG) is a rare and debilitating neutrophilic-driven, autoinflammatory disease, characterized by an acute, destructive ulcerating process of the skin, primarily occurring on the legs.

  • GlobeNewswire12 days ago

    InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa

    IFX-1 did not demonstrate a statistically significant dose dependent effect on Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 16 as primary endpoint IFX-1.

  • GlobeNewswire25 days ago

    InflaRx Reports First Quarter 2019 Financial & Operating Results

    IFX-1: New long-term efficacy data from Phase IIa clinical trial in Hidradenitis Suppurativa presented; approval granted to initiate Phase IIa trial in Canada in Pyoderma.

  • GlobeNewswirelast month

    InflaRx Commences Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe

    InflaRx (IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the treatment of the first patient in IXchange, a Phase II study with IFX-1 in patients with ANCA-associated vasculitis (AAV) (NCT03895801). AAV is a rare and life-threatening autoimmune disease in which activation of the complement system, and specifically generation of C5a, is believed to play a key role in the neutrophil-driven vessel inflammation that defines the disease. The main objective of this randomized, double-blind, placebo-controlled Phase II study is to evaluate the efficacy and safety of IFX-1 in patients with moderate to severe AAV.

  • GlobeNewswire3 months ago

    InflaRx Full Year 2018 Financial & Operating Results

    $62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1Start of three Phase II trials for IFX-1 in two serious inflammatory.

  • GlobeNewswire4 months ago

    InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum

    InflaRx N.V. (IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the approval of a Clinical Trial Application by Health Canada for a phase IIa clinical trial evaluating the Company’s lead product candidate, IFX-1, in Pyoderma Gangraenosum. This is the third autoimmune disease for which InflaRx is developing IFX-1.

  • GlobeNewswire4 months ago

    Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire4 months ago

    Richard Brudnick to Join InflaRx Board of Directors

    InflaRx N.V. (IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that Mr. Richard Brudnick has been appointed as interim Non-Executive Director to the Board of Directors of InflaRx N.V. Mr. Brudnick has substantial experience in the biotechnology and healthcare industry and is currently serving as Chief Business Officer and Head of Strategy for Codiak BioSciences. The confirmed appointment of Mr. Brudnick as a Non-Executive Director of the Board is subject to the approval at the Annual General Meeting of Shareholders in May 2019.

  • GlobeNewswire4 months ago

    InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa

    InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today announced that new clinical data with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with moderate to severe Hidradenitis Suppurativa (HS) are to be presented this week at the 8th Conference of the European Hidradenitis Suppurativa Foundation in Wrocław, Poland. HS is a painful and debilitating chronic inflammatory skin disease with limited treatment options.

  • GlobeNewswire5 months ago

    InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management

    InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today announced the opening of the company’s second U.S.-based location and the addition of new management members. The new corporate office follows the opening of the company’s R&D facility in Ann Arbor, MI in June 2018.

  • GlobeNewswire6 months ago

    InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis

    AAV is a rare and life-threatening autoimmune disease in which activation of the complement system, and specifically generation of C5a, is believed to play a key role in the neutrophil-driven vessel inflammation that defines the disease.  AAV affects approximately 40,000 and 75,000 patients in the United States and Europe, respectively. Othmar Zenker, M.D., Chief Medical Officer of InflaRx, said: “We are pleased to be able to move forward with the second phase II study in AAV with IFX-1.  AAV is an orphan disease with high unmet medical need.

  • GlobeNewswire7 months ago

    InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results

    Completion of patient recruitment in phase IIb trial in Hidradenitis SuppurativaFirst patient dosed in phase II trial with IFX-1 in ANCA-associated vasculitis Board of Directors.

  • GlobeNewswire7 months ago

    InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa

    InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today announced that patient enrollment has been completed in the phase IIb study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients suffering from moderate or severe Hidradenitis Suppurativa (HS). HS is a painful and debilitating chronic inflammatory skin disease with limited treatment options.

  • GlobeNewswire8 months ago

    InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing

    InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today announced that the first patient has been dosed in a phase II study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV). AAV is a rare and life-threatening autoimmune disease in which activation of the complement system, and specifically the generation of larger amounts of C5a, is believed to play a key role in the neutrophil-driven vessel inflammation that defines the disease. AAV affects approximately 40,000 and 75,000 patients in the United States and Europe, respectively.